Skip to main content
OpenTrials
Completed

NCT Number: NCT00086502

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient has type 2 diabetes mellitus (T2DM)
  • Patient is 18 years of age (or older)
  • Patient is not pregnant or breast-feeding and does not plan to become pregnant for the duration of the study and poststudy follow-up period

Exclusion criteria

  • Patient has a history of type 1 diabetes mellitus or a history of ketoacidosis
  • Patient required insulin within the prior 8 weeks
  • Patient is on a weight loss program and is not in the maintenance phase
  • Patient started on a weight loss medication (e.g., orlistat or sibutramine) within the prior 8 weeks
  • Patient is on or likely to require treatment with treatment with immunosuppressive agents (e.g., cyclosporin, methotrexate)
  • Patient has cirrhosis, active liver disease (other than fatty liver) or symptomatic gallbladder disease
  • Patient has chronic myopathy, or a progressive neurological or neuromuscular disorder (e.g., multiple sclerosis or polymyositis)
  • Patient has any of the following disorders within the past 6 months:

Acute coronary syndrome (e.g., MI or unstable angina), Coronary artery intervention, Stroke or transient ischemic neurological disorder.

  • Patient has new or worsening signs or symptoms of coronary heart disease within the past 3 months
  • Patient has severe peripheral vascular disease
  • Patient has congestive heart failure
  • Patient is HIV positive
  • Patient has a clinically important hematological disorder (e.g., aplastic anemia, myeloproliferative or myelodysplastic syndromes, thrombocytopenia)
  • Patient has a history of neoplastic disease
  • Patient has a history of alcohol or drug abuse within the past 3 years
  • Patient has viral hepatitis (hepatitis B or C)

Treatment and study plan

Comparator: Sitagliptin

Drug

Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24

Other names: Januvia

Comparator: placebo

Drug

Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24

Comparator: pioglitazone

Drug

Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8

Other names: ACTOS

metformin

Drug

Metformin rescue for patients meeting

pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8

Primary outcomes

  1. Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24

    Time frame: Baseline and week 24

    HbA1c is measured as a percent. Thus, this change from baseline reflects the Week 24 HbA1c percent minus the Week 0 HbA1c percent.

Secondary outcomes

  1. Change From Baseline in FPG (Fasting Plasma Glucose) at Week 24

    Time frame: Baseline and week 24

    Change from baseline at Week 24 is defined as Week 24 minus Week 0.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of the Addition of MK0431 to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Pioglitazone Therapy

Important dates

Study start
2004
Primary completion
2005
Study completion
2005
First posted
Jul 5, 2004
Registry last updated
Feb 5, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.